Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
MWN-AI** Summary
Baxter International Inc. has unveiled its innovative IV Verify Line Labeling System during the 2026 American Organization for Nursing Leadership Conference. This automated solution is designed to enhance intravenous (IV) line labeling in healthcare settings, aiming to improve medication administration safety and streamline nursing workflows. Traditional handwritten labeling in high-acuity areas often leads to medication errors due to inconsistencies and unclear labeling practices. A study in 10 hospitals revealed that 60% of IV infusion labels did not meet compliance standards, highlighting the need for a better solution.
The IV Verify system addresses this challenge by enabling clinicians to scan a medication barcode, which triggers the instant printing of a three-part adhesive label containing critical information such as the drug name, administration time, and tubing change timings. This system not only standardizes IV line labeling but also reduces the cognitive burden on nurses, allowing them to focus more on patient care. Clinicians using the IV Verify system reportedly saved one to two minutes per IV setup, a significant gain in healthcare settings where time is of the essence.
Furthermore, the color-coded labels printed by the system are liquid-resistant and designed to remain legible even in busy clinical environments, thus enhancing clarity and reducing risks associated with medication administration. By replacing handwritten labels with a consistent, automated process, Baxter’s IV Verify system is poised to provide substantial improvements in patient safety and nurse efficiency. Available in the U.S. now, this product underscores Baxter’s commitment to advancing healthcare practices through actionable, clinician-focused innovation.
MWN-AI** Analysis
Baxter International Inc. (NYSE: BAX) has recently introduced the IV Verify Line Labeling System, an innovative automated solution designed to enhance IV line labeling within healthcare settings. This initiative reflects Baxter's commitment to improving patient safety and nursing efficiency — two critical factors that can significantly impact healthcare outcomes.
From a market perspective, the IV Verify system presents an attractive investment opportunity, particularly as the healthcare industry increasingly prioritizes technology that enhances patient safety and operational efficiency. With medication errors being a persistent issue, particularly in high-acuity environments, Baxter's solution addresses a glaring need for standardized labeling practices. The recent statistics indicating that 60% of IV infusion labels were not compliant with hospital policies highlight the urgency for solutions like IV Verify.
Investors should also consider the potential for Baxter to capture a larger market share through the exclusive distribution agreement with Vigilant Software, combining expertise in medication safety with Baxter's established market presence. The focus on automation and ease of use positions the IV Verify system as a game-changer in healthcare, appealing to both clinicians and hospital administrators concerned about costs associated with medication errors.
Moreover, the IV Verify system’s ability to streamline nursing workflows and reduce cognitive burdens will likely foster a positive reception among healthcare providers. Evidence of improved labeling compliance and a reduction in central line-associated bloodstream infections (CLABSI) within healthcare systems that have implemented the technology underline its efficacy.
In conclusion, with increasing regulatory scrutiny around patient safety and the growing demand for process automation in healthcare, Baxter's IV Verify presents a timely and relevant advancement. Investors looking for growth in the healthcare tech sector would be wise to monitor Baxter's performance post-launch, as its success may provide a significant boost to the company’s long-term value.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- New system offers a standardized and simplified alternative to traditional handwritten line labeling that supports safer medication administration
- Solution aims to streamline nursing workflow, helping to save clinician time and reduce likelihood of medication errors related to IV line labeling inconsistencies
Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solution, at the 2026 American Organization for Nursing Leadership Conference. The IV Verify system is designed to streamline nursing workflows, save clinician time and support safer medication administration at the bedside. Baxter’s launch of the product is the result of a strategic and exclusive distribution agreement with Vigilant Software, a leader in medication management safe practices.
Medication errors remain a persistent challenge in healthcare settings, particularly in high-acuity areas where multiple infusions may be running simultaneously. Unclear or inconsistent IV line labeling practices can contribute to line tracing errors or incorrect medication administration. i,ii In a 10-hospital study of intensive care units (ICUs), 60 percent of IV infusion labels were not compliant with hospital policies. i With the IV Verify system, clinicians scan a medication’s barcode and the system instantly prints a three-part adhesive label featuring the drug name, administration time and tubing change times, which can then be applied to the tubing – offering a clear, simplified solution that can help support patient safety and labeling compliance.
“Frontline clinicians manage complexity every day, and even small inefficiencies can create risk,” said Athar Mirza, U.S. and Canada general manager of Baxter’s Infusion Therapies and Platforms division. “At Baxter, we are committed to supporting nurses at the bedside with tools that can help make care safer and more efficient. The IV Verify system replaces handwritten labels with easy-to-use technology that supports consistency, saves time and helps clinicians confidently trace IV lines so they can spend more time focused on their patients.”
The IV Verify system includes a printer, labels and patented ink-free technology and is designed to support:
- Patient Safety : Replaces inconsistent handwritten line labels with clear, standardized identification to help reduce the risk of medication error and support safe infusion practices at the bedside. One healthcare system saw increased compliance in line labeling at the point of care when using the IV Verify system, and a meaningful reduction in central line associated blood stream infections (CLABSI) when implemented as part of a health system’s CLABSI bundle. iii
- Nurse Efficiency : Streamlines IV line identification and tracing, helping clinicians save time and reduce cognitive burden. Color-coded labels indicate tubing change day and time, which aims to eliminate the need for manual calculations of line expiration. Additionally, studies show that clinicians saved an average of one to two minutes per IV setup with the IV Verify system, time that can be redirected to patient interactions. iv
- Clarity : System prints color-coded and liquid-resistant labels designed to remain legible in busy clinical environments where multiple infusions may be running at the same time. Two additional labels – closer to the infusion pump and patient ends of tubing – aim to provide greater clarity compared to the traditional single, handwritten label.
The introduction of the IV Verify Line Labeling System reflects Baxter’s ongoing commitment to helping advance safer infusion practices through practical, clinician-focused innovation. The product is available now in the U.S. Learn more here .
Vigilant Software is a healthcare technology company founded by a practicing clinician and focused on supporting medication safety and clinical workflow through automation.
About Baxter
At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician’s office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X , LinkedIn and Facebook .
Rx Only . For safe and proper use of this device, refer to the full Instructions for Use.
This release includes forward-looking statements concerning potential benefits associated with IV Verify . The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand and market acceptance for, and competitive pressures (including pricing) related to, new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.
Baxter is a registered trademark of Baxter International Inc.
IV VERIFY is a trademark of Vigilant Labs, Inc. and is used under license.
i Schnock K, Dykes P, Albert J, et al. The frequency of intravenous medication administration errors related to smart infusion pumps: a multihospital observational study. BMJ Qual Saf. 2017. 26(2):131-140. |
ii Lassiter Z, Brockman B, Brown M, et al. Enhancing CLABSI prevention through smart IV tubing labeling technology: a quality improvement project to improve bundle compliance and reduce nursing burden. Poster presented at: AVA Annual Scientific Meeting; 2025; Kissimmee, Florida. |
iii Hinton A and Olson J. Utilizing Technology: Increasing IV Tubing Labeling Compliance to Prevent Central Line Associated Blood Stream Infection (CLABSI). Indiana University Health. 2022. |
iv Tinio GR, Meister U. On-demand IV infusion label printer. Northwestern Medicine–Delnor Hospital; 2017. Internal report. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260330045112/en/
Media Contact
Brenna Byrne, (224) 948-5353
media@baxter.com
Investor Contact
Kevin Moran, (224) 948-3085
global_corp_investor_relations@baxter.com
FAQ**
How does Baxter International Inc. BAX plan to measure the effectiveness of the IV Verify Line Labeling System in reducing medication errors within healthcare settings post-launch?
What competitive advantages does Baxter International Inc. BAX foresee with the introduction of the IV Verify system as compared to traditional handwritten labeling methods?
Given the potential demand for the IV Verify Line Labeling System, what strategies does Baxter International Inc. BAX have in place to scale production and manage supply chain challenges?
What feedback has Baxter International Inc. BAX received from healthcare providers regarding the integration of the IV Verify system into existing workflows, particularly in high-acuity areas?
**MWN-AI FAQ is based on asking OpenAI questions about Baxter International Inc. (NYSE: BAX).
NASDAQ: BAX
BAX Trading
2.41% G/L:
$19.735 Last:
2,499,729 Volume:
$19.46 Open:
